Morgan Stanley’s CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) CYNA Stock Holding History

Morgan Stanley’s Portfolio CYNA Stock Details CYNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-101,186	Closed	-$4.07M	–	6693
2016 Q3	$4.07M	Buy	101,186 +99,486	+5,852%	+$2.46M	﹤0.01%	2875
2016 Q2	$28K	Buy	1,700 +1,580	+1,317%	+$21.3K	﹤0.01%	5739
2016 Q1	$1K	Buy	120 +99	+471%	+$1.33K	﹤0.01%	6520
2015 Q4	$0	Sell	21 -842	-98%	-$12.8K	﹤0.01%	6951
2015 Q3	$14K	Buy	+863	New	+$14K	﹤0.01%	6172

Morgan Stanley's CYNA Position: Q4 2016 in Review

Morgan Stanley sold out of CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) (CYNA) in Q4 2016, closing a stake of 101,186 shares — an estimated $4.07M sold.

Morgan Stanley first reported a position in CYNA in Q3 2015 and held it in 5 quarters. The position peaked at $4.07M in Q3 2016. 0 funds tracked by Wall St. Rank hold CYNA as of Q4 2016.

Morgan Stanley reported no remaining CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) position as of Q4 2016 after selling out during the quarter.
Morgan Stanley sold 101,186 CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) shares in Q4 2016, an estimated $4.07M.
Morgan Stanley first reported a position in CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q3 2015 and held it in 5 quarters.
Morgan Stanley's CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) position peaked at $4.07M in Q3 2016.
0 funds tracked by Wall St. Rank held CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) as of Q4 2016.

Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.